Astrazeneca Pharma India Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8233 as of 05 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2021 .The P/E Ratio of Novelix Pharmaceuticals Ltd is 0 as of March 2021 . The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2021 .The Market Cap of Novelix Pharmaceuticals Ltd is ₹ 5.48 crore as of March 2021 . The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 48.4 crore as compare to the Sep '25 revenue of ₹ 36.39 crore. This represent the growth of 33% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 1.31 crore as compare to the Sep '25 ebitda of ₹ 0.73 crore. This represent the growth of 79.45% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Novelix Pharmaceuticals Ltd changed from ₹ -0.35 crore to ₹ 1 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Novelix Pharmaceuticals Ltd

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Novelix Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,116 Cr while Market cap of Novelix Pharmaceuticals Ltd is 58 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd?

As of May 5, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8046.55. On the other hand, Novelix Pharmaceuticals Ltd stock price is INR ₹40.5.

How do dividend payouts of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.